294 related articles for article (PubMed ID: 11919262)
21. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
22. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
23. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
24. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
25. Ovarian ablation as a treatment for breast cancer.
Sainsbury R
Surg Oncol; 2003 Dec; 12(4):241-50. PubMed ID: 14998564
[TBL] [Abstract][Full Text] [Related]
26. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Du XL
J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
[No Abstract] [Full Text] [Related]
27. Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF; Arick CL
Cancer Invest; 2001; 19(7):706-22. PubMed ID: 11577812
[No Abstract] [Full Text] [Related]
28. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
29. New insights into endocrine therapy for young women with breast cancer.
Di Lascio S; Pagani O
Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
[TBL] [Abstract][Full Text] [Related]
30. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
Malayeri R
J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
[No Abstract] [Full Text] [Related]
31. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
33. Does the addition of chemotherapy to adjuvant endocrine treatment add any benefit in ER-positive early breast cancer: can we rely on large randomized control trials in the era of personalized medicine?
Glück S
Ann Oncol; 2011 Sep; 22(9):1937-1938. PubMed ID: 21765047
[No Abstract] [Full Text] [Related]
34. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
Paridaens RJ; Gelber S; Cole BF; Gelber RD; Thürlimann B; Price KN; Holmberg SB; Crivellari D; Coates AS; Goldhirsch A
Breast Cancer Res Treat; 2010 Aug; 123(1):303-10. PubMed ID: 20195744
[TBL] [Abstract][Full Text] [Related]
35. [Current issues in adjuvant hormone therapy of breast cancer].
Semiglazov VF; Semiglazov VV
Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
[No Abstract] [Full Text] [Related]
36. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
38. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
39. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy for all patients with breast cancer?
Lippman ME; Hayes DF
J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
